Supplemental material
Scandinavian Journal of Gastroenterology
Volume 54, 2019 - Issue 6
Original Article
Pharmacokinetics of golimumab in moderate to severe ulcerative colitis: the GO-KINETIC study
Sophie E. BerendsDepartment of Gastroenterology and Hepatology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands; ;Hospital Pharmacy, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands; 
http://orcid.org/0000-0002-3236-0698View further author information
http://orcid.org/0000-0002-3236-0698View further author information, Anne S. StrikDepartment of Gastroenterology and Hepatology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands; http://orcid.org/0000-0001-8879-4359View further author information
http://orcid.org/0000-0001-8879-4359View further author information, , , , , , & show allRelated Research Data
Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up
Source:
American Medical Association (AMA)
Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis
Source:
Elsevier BV
Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies
Source:
Oxford University Press (OUP)
Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis
Source:
Elsevier BV
Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis
Source:
Elsevier BV
P226 Comparison of four different immunoassays for measuring golimumab and anti-golimumab antibody concentration in patients with ulcerative colitis
Source:
Oxford University Press (OUP)
Patient Factors That Increase Infliximab Clearance and Shorten Half-life in Inflammatory Bowel Disease
Source:
Oxford University Press (OUP)
Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis
Source:
Elsevier BV
Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis
Source:
Wiley-Blackwell
Pharmacokinetics of golimumab in moderate to severe ulcerative colitis: the GO-KINETIC study
Source:
Taylor & Francis
Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials.
Source:
Elsevier BV
Association Between Serum Concentration of Infliximab and Efficacy in Adult Patients With Ulcerative Colitis
Source:
Elsevier BV
Pharmacokinetics of golimumab in moderate to severe ulcerative colitis: the GO-KINETIC study
Source:
Taylor & Francis
Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.
Source:
Elsevier BV
Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn's disease
Source:
Wiley
Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis
Source:
Wiley-Blackwell
An Accelerated Infliximab Induction Regimen Reduces the Need for Early Colectomy in Patients With Acute Severe Ulcerative Colitis
Source:
Elsevier BV
Linking provided by
